Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations
Health Economics · 2025-01 · 34 (1) · 85-104
DOI: 10.1002/hec.4903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Economics, online erschienen am 26.09.2024. Verfasst von David G Lugo-Palacios und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.
Abstract (Originalsprache)
Methods have been developed for transporting evidence from randomised controlled trials (RCTs) to target populations. However, these approaches allow only for differences in characteristics observed in the RCT and real‐world data (overt heterogeneity). These approaches do not recognise heterogeneity of treatment effects (HTE) according to unmeasured characteristics (essential heterogeneity). We use a target trial design and apply a local instrumental variable (LIV) approach to electronic health records from the Clinical Practice Research Datalink, and examine both forms of heterogeneity in assessing the comparative effectiveness of two second‐line treatments for type 2 diabetes mellitus. We first estimate individualised estimates of HTE across the entire target population defined by applying eligibility criteria from national guidelines ( n = 13,240) within an overall target trial framework. We define a subpopulation who meet a published RCT's eligibility criteria (‘RCT‐eligible’, n = 6497), and a subpopulation who do not (‘RCT‐ineligible’, n = 6743). We compare average treatment effects for pre‐specified subgroups within the RCT‐eligible subpopulation, the RCT‐ineligible subpopulation, and within the overall target population. We find differences across these subpopulations in the magnitude of subgroup‐level treatment effects, but that the direction of estimated effects is stable. Our results highlight that LIV methods can provide useful evidence about treatment effect heterogeneity including for those subpopulations excluded from RCTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
- Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
- The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, Washington, USA.
- Diabetes Trials Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, OCDEM Building Churchill Hospital, Headington, UK.
- Department of Statistical Science, University College London, London, UK.
ORCID-Profile: David G Lugo-Palacios, Anirban Basu, Andrew Briggs, Richard Grieve
Förderung
- National Institute for Health and Care Research
Zitieren
APA
Lugo-Palacios, D. G., Bidulka, P., O'Neill, S., Carroll, O., Basu, A., Adler, A., DíazOrdaz, K., Briggs, A., & Grieve, R. (2025). Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations. Health Economics, 34(1), 85-104. https://doi.org/10.1002/hec.4903
Vancouver
Lugo-Palacios DG, Bidulka P, O'Neill S, Carroll O, Basu A, Adler A, et al. Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations. Health Economics. 2025;34(1):85-104. doi:10.1002/hec.4903
BibTeX
@article{LugoPalacios2025,
author = {Lugo-Palacios, David G and Bidulka, Patrick and O'Neill, Stephen and Carroll, Orlagh and Basu, Anirban and Adler, Amanda and DíazOrdaz, Karla and Briggs, Andrew and Grieve, Richard},
title = {Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations},
journal = {Health Economics},
year = {2025},
volume = {34},
number = {1},
pages = {85--104},
doi = {10.1002/hec.4903}
}
EUVIMED